세계의 항-CD20 단클론항체 시장 보고서(2025년)

Anti-CD20 monoclonal antibodies are targeted immunotherapies designed to bind to the CD20 protein found on the surface of B-cells. These antibodies initiate immune responses such as complement activation and antibody-dependent cell-mediated cytotoxicity, aiding in the destruction of abnormal or malignant B-cells. This focused treatment strategy allows for greater precision and fewer systemic side effects compared to traditional chemotherapy.

The primary types of anti-CD20 monoclonal antibodies include rituximab, obinutuzumab, ofatumumab, and others. Rituximab, which targets CD20, is commonly used in the treatment of B-cell malignancies and autoimmune disorders by depleting abnormal B-cells. It is available in various administration routes, including intravenous and subcutaneous, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online platforms. Rituximab is employed in the treatment of conditions like non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, multiple sclerosis, pemphigus vulgaris, and others. It is utilized by a range of end-users, including hospitals, surgical and diagnostic centers, maternity facilities, ambulatory care units, academic institutions, and other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The anti-CD20 monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides anti-CD20 monoclonal antibodies market statistics, including the anti-CD20 monoclonal antibodies industry global market size, regional shares, competitors with the anti-CD20 monoclonal antibodies market share, detailed anti-CD20 monoclonal antibodies market segments, market trends, opportunities, and any further data you may need to thrive in the anti-CD20 monoclonal antibodies industry. This anti-CD20 monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anti-CD20 monoclonal antibodies market size has grown strongly in recent years. It will grow from $8.33 billion in 2024 to $9.00 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to the increasing prevalence of B-cell malignancies, the expanding use of anti-CD20 therapies in treating autoimmune diseases, a rise in FDA and EMA approvals for new anti-CD20 treatments, and the global increase in the geriatric population.

The anti-CD20 monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.05 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to a rise in strategic collaborations and licensing agreements, broader application in combination therapies, an increasing number of relapsed or refractory cases, higher healthcare spending and improved access in emerging markets, and the continued development and approval of biosimilars. Key trends expected during this period include innovations in monoclonal antibody engineering, the integration of anti-CD20 antibodies into combination treatment regimens, technology-enabled personalization of cancer therapies, advancements in subcutaneous and long-acting formulations, and progress in bispecific and next-generation antibody development.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the anti-CD20 monoclonal antibodies market. Autoimmune diseases arise when the immune system mistakenly targets the body's own cells, treating them as foreign invaders. The increase in autoimmune conditions is linked to greater exposure to environmental pollutants, which can disrupt immune regulation and provoke attacks on the body's tissues. Anti-CD20 monoclonal antibodies help manage autoimmune diseases by targeting and removing B cells responsible for producing autoantibodies and causing inflammation. These therapies aid in regulating immune activity and alleviating disease symptoms. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that in 2022, approximately 514,000 people (2.0%) in Australia were living with rheumatoid arthritis, a systemic autoimmune condition, affecting 2.5% of females and 1.6% of males. Thus, the increasing incidence of autoimmune diseases is contributing to the growth of the anti-CD20 monoclonal antibodies market.

Major players in the anti-CD20 monoclonal antibody market are advancing the development of new therapies such as obinutuzumab to address resistant or relapsed B-cell malignancies more effectively. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that targets and eliminates CD20-positive B cells involved in certain blood cancers and autoimmune disorders. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical firm, announced that the US Food and Drug Administration (FDA) had accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis. This submission is based on positive results from the Phase III REGENCY study, which demonstrated improved complete renal response (CRR) when the drug was combined with standard therapy compared to standard therapy alone. This positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to show such benefits in treating lupus nephritis, a serious kidney inflammation caused by lupus.

In August 2023, TG Therapeutics, a US-based manufacturer of anti-CD20 monoclonal antibodies, formed a partnership with Neuraxpharm to expand the global availability of its multiple sclerosis treatment. The collaboration aims to commercialize BRIUMVI, a CD20-targeted monoclonal antibody therapy, in international markets and increase access for patients with relapsing multiple sclerosis outside the United States. Neuraxpharm is a pharmaceutical company headquartered in Germany.

Major players in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH.

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-CD20 monoclonal antibodies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-CD20 monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-CD20 monoclonal antibodies market consists of sales of tositumomab, ocrelizumab, ublituximab, and mosunetuzumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-CD20 Monoclonal Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-cd20 monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-cd20 monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-cd20 monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Rituximab; Obinutuzumab; Ofatumumab; Other Product Types
• 2) By Route Of Administration: Intravenous; Subcutaneous
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Non-Hodgkin's Lymphoma (NHL); Chronic Lymphocytic Leukemia (Cll); Rheumatoid Arthritis; Multiple Sclerosis; Pemphigus Vulgaris; Other Applications
• 5) By End-User: Hospitals; Surgical Centers and Diagnostic Centers; Maternity Centers; Ambulatory Care Centers; Research And Academia; Other End-Users
• Subsegments:
• 1) By Rituximab: Rituxan; Truxima; Ruxience; Reditux
• 2) By Obinutuzumab: Gazyva; Biosimilar Candidates
• 3) By Ofatumumab: Arzerra; Kesimpta
• 4) By Other Product Types: Ublituximab; Veltuzumab; Ocrelizumab; Mosunetuzumab
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; GlaxoSmithKline plc; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals, Inc.; Chugai Pharmaceutical Co. Ltd.; Dr. Reddy's Laboratories; Genmab A/S; Celltrion Inc.; Innovent Biologics; Immunomedics; HLL Lifecare Limited; Shanghai Henlius Biotech Inc.; TG Therapeutics; Biogen Idec; Aetos Pharma; Nycomed GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anti-CD20 Monoclonal Antibodies Market Characteristics

3. Anti-CD20 Monoclonal Antibodies Market Trends And Strategies

4. Anti-CD20 Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anti-CD20 Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anti-CD20 Monoclonal Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anti-CD20 Monoclonal Antibodies Market Growth Rate Analysis
• 5.4. Global Anti-CD20 Monoclonal Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anti-CD20 Monoclonal Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anti-CD20 Monoclonal Antibodies Total Addressable Market (TAM)

6. Anti-CD20 Monoclonal Antibodies Market Segmentation

• 6.1. Global Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituximab
• Obinutuzumab
• Ofatumumab
• Other Product Types
• 6.2. Global Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcutaneous
• 6.3. Global Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Anti-CD20 Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Hodgkin's Lymphoma (NHL)
• Chronic Lymphocytic Leukemia (Cll)
• Rheumatoid Arthritis
• Multiple Sclerosis
• Pemphigus Vulgaris
• Other Applications
• 6.5. Global Anti-CD20 Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Surgical Centers And Diagnostic Centers
• Maternity Centers
• Ambulatory Care Centers
• Research And Academia
• Other End-Users
• 6.6. Global Anti-CD20 Monoclonal Antibodies Market, Sub-Segmentation Of Rituximab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituxan
• Truxima
• Ruxience
• Reditux
• 6.7. Global Anti-CD20 Monoclonal Antibodies Market, Sub-Segmentation Of Obinutuzumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gazyva
• Biosimilar Candidates
• 6.8. Global Anti-CD20 Monoclonal Antibodies Market, Sub-Segmentation Of Ofatumumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Arzerra
• Kesimpta
• 6.9. Global Anti-CD20 Monoclonal Antibodies Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ublituximab
• Veltuzumab
• Ocrelizumab
• Mosunetuzumab

7. Anti-CD20 Monoclonal Antibodies Market Regional And Country Analysis

• 7.1. Global Anti-CD20 Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anti-CD20 Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-CD20 Monoclonal Antibodies Market

• 8.1. Asia-Pacific Anti-CD20 Monoclonal Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-CD20 Monoclonal Antibodies Market

• 9.1. China Anti-CD20 Monoclonal Antibodies Market Overview
• 9.2. China Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-CD20 Monoclonal Antibodies Market

• 10.1. India Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-CD20 Monoclonal Antibodies Market

• 11.1. Japan Anti-CD20 Monoclonal Antibodies Market Overview
• 11.2. Japan Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-CD20 Monoclonal Antibodies Market

• 12.1. Australia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-CD20 Monoclonal Antibodies Market

• 13.1. Indonesia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-CD20 Monoclonal Antibodies Market

• 14.1. South Korea Anti-CD20 Monoclonal Antibodies Market Overview
• 14.2. South Korea Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-CD20 Monoclonal Antibodies Market

• 15.1. Western Europe Anti-CD20 Monoclonal Antibodies Market Overview
• 15.2. Western Europe Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-CD20 Monoclonal Antibodies Market

• 16.1. UK Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-CD20 Monoclonal Antibodies Market

• 17.1. Germany Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-CD20 Monoclonal Antibodies Market

• 18.1. France Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-CD20 Monoclonal Antibodies Market

• 19.1. Italy Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-CD20 Monoclonal Antibodies Market

• 20.1. Spain Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-CD20 Monoclonal Antibodies Market

• 21.1. Eastern Europe Anti-CD20 Monoclonal Antibodies Market Overview
• 21.2. Eastern Europe Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-CD20 Monoclonal Antibodies Market

• 22.1. Russia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-CD20 Monoclonal Antibodies Market

• 23.1. North America Anti-CD20 Monoclonal Antibodies Market Overview
• 23.2. North America Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-CD20 Monoclonal Antibodies Market

• 24.1. USA Anti-CD20 Monoclonal Antibodies Market Overview
• 24.2. USA Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-CD20 Monoclonal Antibodies Market

• 25.1. Canada Anti-CD20 Monoclonal Antibodies Market Overview
• 25.2. Canada Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-CD20 Monoclonal Antibodies Market

• 26.1. South America Anti-CD20 Monoclonal Antibodies Market Overview
• 26.2. South America Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-CD20 Monoclonal Antibodies Market

• 27.1. Brazil Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-CD20 Monoclonal Antibodies Market

• 28.1. Middle East Anti-CD20 Monoclonal Antibodies Market Overview
• 28.2. Middle East Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-CD20 Monoclonal Antibodies Market

• 29.1. Africa Anti-CD20 Monoclonal Antibodies Market Overview
• 29.2. Africa Anti-CD20 Monoclonal Antibodies Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anti-CD20 Monoclonal Antibodies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anti-CD20 Monoclonal Antibodies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-CD20 Monoclonal Antibodies Market Competitive Landscape And Company Profiles

• 30.1. Anti-CD20 Monoclonal Antibodies Market Competitive Landscape
• 30.2. Anti-CD20 Monoclonal Antibodies Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Anti-CD20 Monoclonal Antibodies Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Regeneron Pharmaceuticals, Inc.
• 31.4. Chugai Pharmaceutical Co. Ltd.
• 31.5. Dr. Reddy's Laboratories
• 31.6. Genmab A/S
• 31.7. Celltrion Inc.
• 31.8. Innovent Biologics
• 31.9. Immunomedics
• 31.10. HLL Lifecare Limited
• 31.11. Shanghai Henlius Biotech Inc.
• 31.12. TG Therapeutics
• 31.13. Biogen Idec
• 31.14. Aetos Pharma
• 31.15. Nycomed GmbH

32. Global Anti-CD20 Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-CD20 Monoclonal Antibodies Market

34. Recent Developments In The Anti-CD20 Monoclonal Antibodies Market

35. Anti-CD20 Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

• 35.1 Anti-CD20 Monoclonal Antibodies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anti-CD20 Monoclonal Antibodies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anti-CD20 Monoclonal Antibodies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer